

## CORRECTION


# Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Sara Costa-Cabral, Rachel Brough, Asha Konde, Marieke Aarts, James Campbell, Eliana Marinari, Jenna Riffell, Alberto Bardelli, Christopher Torrance, Christopher J. Lord, Alan Ashworth

There is an error in the Correction published on April 20, 2017. The correct affiliation for the eighth author, Alberto Bartelli, is Candiolo Cancer Institute-FPO, IRCCS, Candiolo, TO, Italy and Department of Oncology, University of Torino, Candiolo, TO 10060, Italy.

## References

1. Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, et al. (2016) CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS ONE 11(2): e0149099. <https://doi.org/10.1371/journal.pone.0149099> PMID: 26881434
2. Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, et al. (2017) Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS ONE 12(4): e0176578. <https://doi.org/10.1371/journal.pone.0176578> PMID: 28426773



## OPEN ACCESS

**Citation:** Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, et al. (2018) Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS ONE 13(10): e0206729. <https://doi.org/10.1371/journal.pone.0206729>

**Published:** October 26, 2018

**Copyright:** © 2018 Costa-Cabral et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.